HepaRegeniX initiates first-in-man Phase 1 trial for its lead MKK4 ...
HepaRegeniX begins Phase 1 trial for HRX-0215, a MKK4 inhibitor aimed at treating liver diseases by enhancing liver regeneration. The trial involves 48 healthy males to evaluate safety and pharmacokinetics. Preclinical studies showed HRX-0215's efficacy in liver disease models, marking a significant step towards new liver disease treatments.
Reference News
HepaRegeniX initiates first-in-man Phase 1 trial for its lead MKK4 ...
HepaRegeniX begins Phase 1 trial for HRX-0215, a MKK4 inhibitor aimed at treating liver diseases by enhancing liver regeneration. The trial involves 48 healthy males to evaluate safety and pharmacokinetics. Preclinical studies showed HRX-0215's efficacy in liver disease models, marking a significant step towards new liver disease treatments.